3-(4-methylpiperazin-1-yl)-1-phenylpropan-1-one | 60868-01-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(4-methylpiperazin-1-yl)-1-phenylpropan-1-one
• 英文别名: 3-(4-Methylpiperazino)propiophenone；3-(4-methyl-piperazin-1-yl)-1-phenyl-propan-1-one；3-(4-methyl-piperazino)-1-phenyl-propan-1-one；3-(4-Methyl-piperazino)-1-phenyl-propan-1-on；2-(N-methylpiperazyl)ethylphenylketone；3-(4-Methyl-piperazino)-1-phenyl-propanon-(1)；1-Methyl-4-(2-benzoylethyl)piperazine
• CAS: 60868-01-1
• 化学式: C₁₄H₂₀N₂O
• 分子量: 232.326
• InChiKey: IXSWJVREQYYLIX-UHFFFAOYSA-N

物化性质

• 熔点：
  38-40 °C
• 沸点：
  120-126 °C(Press: 3.5 Torr)
• 密度：
  1.046±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-methylpiperazin-1-yl)-1-phenylpropan-1-one 在 sodium hydroxide 、 sodium tetrahydroborate 作用下， 以 sodium hydroxide 、 乙醇 、 水 为溶剂， 反应 2.5h， 以91%的产率得到1-methyl-4-(3'-phenyl-3'-hydroxypropyl)piperazine
  参考文献：
  名称：

  Valenta, Vladimir; Bartosova, Marie; Protiva, Miroslav, Collection of Czechoslovak Chemical Communications, 1981, vol. 46, # 5, p. 1280 - 1287

  摘要：

  DOI：
• 作为产物：
  描述：

  N-甲基哌嗪 在 盐酸 作用下， 以 乙醇 、 苯 为溶剂， 反应 14.0h， 生成 3-(4-methylpiperazin-1-yl)-1-phenylpropan-1-one
  参考文献：
  名称：

  Hypolipidemic effects of α, β, and γ-alkylaminophenone analogs in rodents

  摘要：

  A number of N-substituted beta-alkylaminophenone derivatives including two alpha- and two gamma-alkylaminophenone analogs were synthesized and investigated for hypolipidemic activity in mice at 8 mg/kg/day ip. Most of these analogs were found to be significantly more active than lovastatin and clofibrate. N-Phenylpiperazinopropiophenone 16 was one of the best derivatives, lowering serum cholesterol levels 41% and serum triglyceride levels 48% after 16 days of drug administration in CF1 mice. In Sprague-Dawley rats, N-phenylpiperazinopropiophenone at 8 mg/kg/day orally also demonstrated more potent hypolipidemic activity than clofibrate, gemfibrozil, and lovastatin at their therapeutic dosage. It significantly reduced tissue cholesterol and triglyceride levels in the aorta wall tissue and lowered the cholesterol and triglyceride levels in chylomicron, very low density lipid (VLDL) and low density lipid (LDL) fractions, while it significantly elevated the cholesterol levels in high density lipid (HDL) fraction. This compound also proved to be active in lowering both cholesterol and triglyceride levels in hyperlipidemic mice and rats induced with atherogenic diet. In vitro liver acetyl coenzyme A (CoA) synthetase, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase, acyl CoA cholesterol acyl transferase (ACAT), sn-glycerol-3-phosphate acyltransferase, phosphatidylate phosphohydrolase, and hepatic lipoprotein lipase activities were significantly inhibited by N-phenylpiperazinopropiophenone from 25 to 100 mu M.

  DOI：

  10.1016/0223-5234(96)80365-5

文献信息

• Cu-Catalyzed Sequential Dehydrogenation–Conjugate Addition for β-Functionalization of Saturated Ketones: Scope and Mechanism
  作者：Xiaoming Jie、Yaping Shang、Xiaofeng Zhang、Weiping Su

  DOI：10.1021/jacs.6b01337

  日期：2016.5.4

  The first copper-catalyzed direct β-functionalization of saturated ketones is reported. This protocol enables diverse ketones to couple with a wide range of nitrogen, oxygen and carbon nucleophiles in generally good yields under operationally simple conditions. The detailed mechanistic studies including kinetic studies, KIE measurements, identification of reaction intermediates, EPR and UV-visible

  报道了第一个铜催化的饱和酮直接β-官能化。该协议使不同的酮能够在操作简单的条件下以通常良好的产率与广泛的氮、氧和碳亲核试剂结合。进行了详细的机理研究，包括动力学研究、KIE 测量、反应中间体的鉴定、EPR 和紫外可见实验，结果表明该反应是通过一种新型的基于自由基的脱氢生成烯酮和随后的共轭加成序列进行的。
• PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME
  申请人：Mikoshiba Katsuhiko

  公开号：US20120277423A1

  公开（公告）日：2012-11-01

  The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R 1 is a substituted or unsubstituted aryl or heterocyclyl group, R 2 , R 3 , and R 4 are hydrogen atoms, n is 2, X is halogen, R 5 and R 6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R 5 and R 6 are not hydrogen atoms at the same time, or R 5 and R 6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.

  本发明涉及：一种具有转谷氨酰胺酶抑制活性的酮化合物，由下式1、2或3表示： 其中R1是取代或未取代的芳基或杂环基团，R2、R3和R4是氢原子，n是2，X是卤素，R5和R6独立地表示氢原子或取代或未取代的C1-C10烷基、芳基或芳烷基团，其中R5和R6不同时为氢原子，或者R5和R6可以共同形成含氮原子（N）的饱和或未饱和的、取代或未取代的杂环基团；包含该化合物的蛋白质交联抑制剂；以及包含该化合物或蛋白质交联抑制剂的用于预防或治疗由蛋白质交联引起的疾病的组合物。
• Small organic molecules that increase the activity of Gelatinase A in ocular cells
  申请人：——

  公开号：US20040068017A1

  公开（公告）日：2004-04-08

  Small organic molecules capable of effecting a “pharmacological trabeculocanalotomy” in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for primary open angle glaucoma.

  能够通过减少近角网状结构作为截留眼内房水的屏障，从而在眼睛中实现“药理性梁切开术”的小有机分子。这些小有机分子通过增加眼细胞中明胶酶A的活性，通过增加细胞膜表达膜型基质金属蛋白酶（MT-MMPs）来增加房水流出，作为原发性开角青光眼的治疗。
• Intracellular Kinase Inhibitors
  申请人：Flynn A. Gary

  公开号：US20070293499A1

  公开（公告）日：2007-12-20

  Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.

  细胞内激酶抑制剂及其在T细胞恶性肿瘤、B细胞恶性肿瘤、自身免疫性疾病和移植器官患者中的治疗用途。
• Therapeutic Agent for Type 2 Diabetes
  申请人：NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY

  公开号：US20160060235A1

  公开（公告）日：2016-03-03

  An object of the present invention is to provide a novel therapeutic agent for a patient with type 2 diabetes, a cause of which is the abnormal synthesis of insulin attributed to the abnormal modification of tRNA Lys (UUU) in pancreatic β cells having Cdkal1 gene mutation. The present inventors have used (1) a screening system using E. coli in which correct translation into luciferase requires frameshift resulting from mistranslation during protein translation, (2) a screening system using the pancreatic islet of Langerhans isolated from a pancreatic β cell-specific Cdkal1-deficient mouse, and (3) a screening system using a pancreatic β cell-specific Cdkal1-deficient mouse, and found that a compound represented by any of the following formulas (I) to (III) can serve as a therapeutic agent for a patient with type 2 diabetes with Cdkal1 gene mutation resulting in the reduced ability to secrete insulin.

  本发明的一个目的是为2型糖尿病患者提供一种新型治疗剂，其原因是由于胰岛素的异常合成归因于胰岛β细胞中tRNALys(UUU)的异常修饰，其具有Cdkal1基因突变。本发明者已经使用了（1）使用大肠杆菌的筛选系统，其中正确的翻译成荧光酶需要在蛋白质翻译过程中由于错误翻译而导致的移码，（2）使用从胰岛β细胞特异性Cdkal1缺陷小鼠中分离的Langerhans胰岛的筛选系统，以及（3）使用胰岛β细胞特异性Cdkal1缺陷小鼠的筛选系统，并发现以下任一式（I）至（III）所代表的化合物可以作为一种治疗剂，用于具有Cdkal1基因突变且导致胰岛素分泌能力降低的2型糖尿病患者。